Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

NCT00044382 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00044382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00044382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2002
Completion date
January 30, 2007
Enrollment
25
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome